American Journal of Hematology

Article	Citations
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management	325
Thrombocytopenia following Pfizer and Moderna SARS‐CoV‐2 vaccination	324
Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management	209
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures	197
2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management	178
BNT162b2 COVID‐19 vaccine is significantly less effective in patients with hematologic malignancies	141
Age‐dependent and gender‐dependent antibody responses against SARS‐CoV‐2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine	131
Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management	128
Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA	128
Intermediate‐dose anticoagulation, aspirin, and in‐hospital mortality in COVID‐19: A propensity score‐matched analysis	120
Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with non‐Hodgkin lymphoma treated with B‐cell depleting immunotherapy	116
Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management	113
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring	110
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study	104
Immune thrombocytopenia in a 22‐year‐old post Covid‐19 vaccine	92
Impact of sickle cell disease on patientsʼ daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY	86
Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management	85
Recommendations for diagnosis and treatment of methemoglobinemia	81
World Health Organization‐defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management	81
POEMS syndrome: 2021 Update on diagnosis, risk‐stratification, and management	80
Combination of CD19 and CD22 CAR‐T cell therapy in relapsed B‐cell acute lymphoblastic leukemia after allogeneic transplantation	73
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality	71
Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma	71
Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments	64
Acute lymphoblastic leukemia: A population‐based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1	64

Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castlema	62
Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment	61
Immune thrombocytopenia (ITP) World Impact Survey (I‐WISh): Impact of ITP on health‐related quality of life	59
Increased blood viscosity and red blood cell aggregation in patients with COVID‐19	58
Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management	57
Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment	55
SARS‐CoV‐2‐reactive antibody detection after SARS‐CoV‐2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell	55
Hepcidin levels predict Covid‐19 severity and mortality in a cohort of hospitalized Italian patients	55
Outcome of infection with omicron SARS‐CoV‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report	51
Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management	50
Ineffectiveness of high‐dose methotrexate for prevention of CNS relapse in diffuse large B‐cell lymphoma	50
Outcome of T‐cell acute lymphoblastic leukemia/lymphoma: Focus on near‐ETP phenotype and differential impact of nelarabine	49
Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: Assessing the long‐term outcomes in COVID‐19 patients	49
Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases	48
Treatment‐free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors	46
Cerebral venous thrombosis post BNT162b2 mRNA SARS‐CoV‐2 vaccination: A black swan event	44
Late‐onset hematological complications post COVID‐19: An emerging medical problem for the hematologist	42
COVID‐19 vaccines and risks of hematological abnormalities: Nested case–control and self‐controlled case series study	41
Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies	41
Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study	40
2021 update on clinical trials in β‐thalassemia	39
The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms	38
Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemia	38
2021 clinical trials update: Innovations in hemophilia therapy	38
Real‐Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT‐HU cohort study	37
Follicular lymphoma: 2023 update on diagnosis and management	37
Optimizing the diagnostic workflow for acute lymphoblastic leukemia by optical genome mapping	36
Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management	35
Anti‐CD19 and anti‐BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem‐cell transplantation for high‐risk newly diagnosed multiple myeloma	35
Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach	34
First‐line treatment of double‐hit and triple‐hit lymphomas: Survival and tolerance data from a retrospective multicenter French study	34
Optical genome mapping for structural variation analysis in hematologic malignancies	34
Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management	34
Lovo‐cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB‐206 study	33
Myelodysplastic syndromes with ring sideroblasts (MDS‐RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN‐RS‐T) – “2021 u	33
Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data	33
Hodgkin lymphoma: 2023 update on diagnosis, risk‐stratification, and management	33
Pregnancy outcomes with hydroxyurea use in women with sickle cell disease	33
EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk‐stratification, and management	33
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes	33
Comparative effectiveness and safety of anticoagulants for the treatment of heparin‐induced thrombocytopenia	31
Large granular lymphocytic leukemia – A retrospective study of 319 cases	31
Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results	31
Comprehensive phenotyping of erythropoiesis in human bone marrow: Evaluation of normal and ineffective erythropoiesis	31
Laboratory testing for ADAMTS13: Utility for TTP diagnosis/exclusion and beyond	30
Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib	30
Prediction of early (4‐week) mortality in acute myeloid leukemia with intensive chemotherapy	30
Revisiting the non‐transfusion‐dependent (NTDT) vs. transfusion‐dependent (TDT) thalassemia classification 10 years later	29
Hairy cell leukemia 2022: Update on diagnosis, risk‐stratification, and treatment	29
Cutaneous T‐cell lymphomas: 2021 update on diagnosis, risk‐stratification, and management	29

Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia	29
Chimeric antigen receptor T‐cells, bispecific antibodies, and antibody‐drug conjugates for multiple myeloma: An update	29
Recent advances in the pathophysiology of PIEZO1‐related hereditary xerocytosis	29
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors	28
Persistence of Ad26.COV2.S‐associated vaccine‐induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies	28
Randomized control trial of oral arginine therapy for children with sickle cell anemia hospitalized for pain in Nigeria	28
Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Fi	28
Cytogenetic and molecular abnormalities in Waldenström's macroglobulinemia patients: Correlations and prognostic impact	27
Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients	27
Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis	27
Basiliximab for steroid‐refractory acute graft‐versus‐host disease: A real‐world analysis	27
Current approaches to management of newly diagnosed multiple myeloma	27
Outcomes of TP53‐mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival	27
Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations	27
Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management	26
Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes	26
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT‐PCR for BCR::ABL1	26
Viscoelastic hemostatic assays: Update on technology and clinical applications	25
Familial thrombocytopenia flare‐up following the first dose of mRNA‐1273 Covid‐19 vaccine	25
Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management	25
Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: A phase 2, open‐label study	25
Fresh vs. frozen allogeneic peripheral blood stem cell grafts: A successful timely option	25
Sequential P‐GEMOX and radiotherapy for early‐stage extranodal natural killer/T‐cell lymphoma: A multicenter study	25
Current approaches to management of high‐risk multiple myeloma	25
2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management	25
Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials	24
Single‐agent cladribine as an effective front‐line therapy for adults with Langerhans cell histiocytosis	24
An artificial intelligence‐assisted diagnostic platform for rapid near‐patient hematology	24
Serologic response to mRNA COVID‐19 vaccination in lymphoma patients	24
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results	24
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients	24
Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: New insights for an old treatment	24
Myeloid and lymphoid vacuolation in VEXAS syndrome	24
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric‐like GIMEMA LAL‐1308 trial	23
Risk factors for severe COVID‐19 in hospitalized sickle cell disease patients: A study of 319 patients in France	23
Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis	23
Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor‐naïve patients with myelofibrosis: Results of a phase II trial	23
Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) c	23
Aggressive T‐cell lymphomas: 2021 Updates on diagnosis, risk stratification and management	23
Fecal microbiota transplantation in patients with acute and chronic graft‐versus‐host disease—spectrum of responses and safety profile. Results from a prospective, multicenter study	23
The International Hemoglobinopathy Research Network (INHERENT): An international initiative to study the role of genetic modifiers in hemoglobinopathies	22
Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25‐year longitudinal study	22
TLR8/TLR7 dysregulation due to a novel TLR8 mutation causes severe autoimmune hemolytic anemia and autoinflammation in identical twins	22
Iron and platelets: A subtle, under‐recognized relationship	22
Risk of mortality from anemia and iron overload in nontransfusion‐dependent β‐thalassemia	22
Reduced global cerebral oxygen metabolic rate in sickle cell disease and chronic anemias	22
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry	22
SARS‐CoV‐2 vaccination in patients with autoimmune cytopenias: The experience of a reference center	21
Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses	21
Overall and complication‐free survival in a large cohort of patients with β‐thalassemia major followed over 50 years	21
JAK2 unmutated erythrocytosis: 2023 Update on diagnosis and management	21
The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes	21
Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice	21
Oxygen gradient ektacytometry‐derived biomarkers are associated with vaso‐occlusive crises and correlate with treatment response in sickle cell disease	21
An effective chemotherapy‐free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome‐positive acute lymphoblastic leukemia	21
Cytomegalovirus kinetics after hematopoietic cell transplantation reveal peak titers with differential impact on mortality, relapse and immune reconstitution	21
Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia	21
Functional role of endothelial transferrin receptor 1 in iron sensing and homeostasis	20
Intravenous high‐dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study	20
Genomic characteristics and prognostic significance of co‐mutatedASXL1/SRSF2acute myeloid leukemia	20
Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia	20
Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open‐label study	20
A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia	20
Adoptive therapy with cytomegalovirus‐specific T cells for cytomegalovirus infection after haploidentical stem cell transplantation and factors affecting efficacy	20
Bispecific T‐cell engagers for treatment of multiple myeloma	20
Diagnostic work‐up for severe aplastic anemia in children: Consensus of the North American Pediatric Aplastic Anemia Consortium	20
The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance	20
Successful treatment of thrombotic thrombocytopenia with cerebral sinus venous thrombosis following Ad26.COV2.S vaccination	20
Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia	19
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients	19
Haploidentical vs matched unrelated donor transplantation for acute myeloid leukemia in remission: A prospective comparative study	19
Cutaneous T‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and management	19
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi‐center, single‐arm, open‐label, phase 2 study	19
Chimeric antigen receptor T‐cells safety: A pharmacovigilance and meta‐analysis study	19
Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm	19
Hemolytic crisis due to Covid‐19 vaccination in a woman with cold agglutinin disease	19
Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T‐cell lymphoma in a Chinese population: A multicenter phase II trial	19
Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success	19
Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survival	19
Cerebral venous thrombosis and myeloproliferative neoplasms: A three‐center study of 74 consecutive cases	18

Severe thrombocytopenia and microangiopathic hemolytic anemia in pregnancy: A guide for the consulting hematologist	18
Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival	18
Vaccine‐induced thrombotic thrombocytopenia following Ad26.COV2.S vaccine in a man presenting as acute venous thromboembolism	18
Sex differences in lymphoma incidence and mortality by subtype: A population‐based study	18
Plasma P‐selectin is an early marker of thromboembolism in COVID‐19	18
Risk factors for severe infection and mortality In patients with COVID‐19 in patients with multiple myeloma and AL amyloidosis	18
BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia	18
Decitabine and venetoclax for IDH1/2‐mutated acute myeloid leukemia	18
Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions	18
Chromosome 1q21 aberrations identify ultra high‐risk myeloma with prognostic and clinical implications	17
Multicenter evaluation of efficacy and toxicity of venetoclax‐based combinations in patients with accelerated and blast phase myeloproliferative neoplasms	17
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)	17
Differentiation syndrome with lower‐intensity treatments for acute myeloid leukemia	17
Momelotinib for myelofibrosis: 12‐year survival data and retrospective comparison to ruxolitinib	17
Marginally reduced maternal hepatic and splenic ferroportin under severe nutritional iron deficiency in pregnancy maintains systemic iron supply	17
Romidepsin and lenalidomide‐based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts	17
A novel 4‐mRNA signature predicts the overall survival in acute myeloid leukemia	17
CDKN2A deletions are associated with poor outcomes in 101 adults with T‐cell acute lymphoblastic leukemia	17
Determination of fitness and therapeutic options in older patients with acute myeloid leukemia	17
The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T‐cell therapy	17
Patient‐reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease	17
Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide study	17
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants	16
Long‐term results of low‐intensity chemotherapy with clofarabine or cladribine combined with low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukem	16
Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor	16
The international consensus classification of eosinophilic disorders and systemic mastocytosis	16
Parenteral iron therapy and phosphorus homeostasis: A review	16
Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma	16
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen	16
Long‐term follow‐up of VIALE‐A: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia	16
Genetic screening of children with marrow failure. The role of primary Immunodeficiencies	16
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk	16
Monoclonal gammopathy of renal significance (MGRS): Real‐world data on outcomes and prognostic factors	16
Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review	16
Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the	15
Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myelo	15
Molecular and clinicopathologic characterization of pediatric histiocytoses	15
Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management	15
Prediction of survival with intensive chemotherapy in acute myeloid leukemia	15
Humanized CD19‐targeted chimeric antigen receptor T (CAR‐T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia	15
Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management	15
Comparison of neutralizing antibody responses against SARS‐CoV‐2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZ	15
Depression in adolescents and young adults with heavy menstrual bleeding in a referral clinic setting	14
Clinical implications of SRSF2 mutations in AML patients undergoing allogeneic stem cell transplantation	14
Haplo‐identical or mismatched unrelated donor hematopoietic cell transplantation for Fanconi anemia: Results from the Severe Aplastic Anemia Working Party of the EBMT	14
Hyper‐inflammation and complement in COVID‐19	14
Daratumumab, lenalidomide, and dexamethasone in systemic light‐chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21	14
The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed o	14
Real‐world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts	14
Epidemiology of clinically significant forms of alpha‐ and beta‐thalassemia: A global map of evidence and gaps	14
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real‐life campus CLL study	14
Major adverse cardiovascular events in survivors of immune‐mediated thrombotic thrombocytopenic purpura	14
Thrombosis is associated with worse survival in children with acute lymphoblastic leukemia: A report from CYP‐C	14
Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases	14
The clinical outcomes and genomic landscapes of acute lymphoblastic leukemia patients with E2A‐PBX1: A 10‐year retrospective study	14
VEXAS syndrome: Clinical, hematologic features and a practical approach to diagnosis and management	14
Clonal hematopoiesis in patients with Covid‐19 is stable and not linked to an aggravated clinical course	14
Intravenous ferric derisomaltose for the treatment of iron deficiency anemia	14
The impact of voxelotor treatment on leg ulcers in patients with sickle cell disease	14
Impact of Philadelphia chromosome‐like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase	14
Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first‐line therapy in multiple myeloma	14
Ruxolitinib in adult patients with secondary hemophagocytic lymphohistiocytosis	14
Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis	14
Assessment of fixed‐duration therapies for treatment‐naïve Waldenström macroglobulinemia	13
Natural gene therapy by reverse mosaicism leads to improved hematology in Fanconi anemia patients	13
Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDS	13
Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post‐autologous stem cell transplantation lenalidomide maintenance therapy	13
Real‐world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts	13
Assessment of the 4‐factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study	13
Molecular and clinical characterization of transient antithrombin deficiency: A new concept in congenital thrombophilia	13
Pregnancy outcomes in women with sickle cell disease in California	13
Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia	13
Outcomes of venetoclax‐based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia	13
COVID‐19 vaccine response in patients with hematologic malignancy: A systematic review and meta‐analysis	13
Loss of alpha‐globin genes in human subjects is associated with improved nitric oxide‐mediated vascular perfusion	13
Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management	13
Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma	13
Multi‐center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era	13
Cerebral oxygen metabolic stress is increased in children with sickle cell anemia compared to anemic controls	13
First and fatal case of autoimmune acquired factor XIII/13 deficiency after COVID‐19/SARS‐CoV‐2 vaccination	13
Expression of p53 protein isoforms predicts survival in patients with multiple myeloma	13
WhiMSICAL: A global Waldenström's Macroglobulinemia patient‐derived data registry capturing treatment and quality of life outcomes	13
Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study	13
Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma	13
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA	13
PD‐L1 overexpression correlates with JAK2‐V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms	13
Serotonin‐release assay‐positive but platelet factor 4‐dependent enzyme‐immunoassay negative: HIT or not HIT?	13
Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE‐A	12
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30‐year experience	12
A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma	12
Sustained, complete response to pexidartinib in a patient with CSF1R‐mutated Erdheim–Chester disease	12
Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B‐cell lymphoma	12
Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN‐003/MYX.1 single arm phase I	12
The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception	12
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers	12